Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app ease the burden for young cancer survivors?

NCT ID NCT04593277

Knowledge-focused Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested an interactive survivorship program for adolescent and young adult cancer survivors. The program included a mobile app, telehealth support, and printed materials to help survivors access healthcare resources, improve self-management skills, and reduce cancer-related distress. The study enrolled 549 survivors of various cancers like leukemia, lymphoma, melanoma, breast, thyroid, and colorectal cancer. Researchers measured changes in distress and healthcare adherence over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
INSPIRE mobile application, control website, telehealth stepped care, printed survivorship materials
What this could lead to
If successful, this program could provide a practical way to help young cancer survivors manage their health after treatment and reduce emotional distress.
What could go wrong
This is a completed study, so results are available but may show limited or no benefit. The program may not work for all survivors or in all healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

549 people

The number who actually took part.

Started

Oct 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with a first invasive malignancy of leukemia, lymphoma, melanoma, sarcoma, breast, thyroid, or colorectal cancer (stage 1-3 for solid tumors) between the ages of 15-39 years * Current age \>= 18 when approached * Currently within 1 to 5 years from the time of diagnosis * Completed active treatment for disease \>= 6 months previously * Received a therapeutic intervention (with curative intent if advanced stage disease) that included any of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy * English proficiency adequate to complete assessments * Access to email and smartphone mobile app and or internet Exclusion Criteria: * Diagnosed with a subsequent invasive malignancy other than non-melanoma skin cancer * Received hematopoietic stem cell transplant * Health issues prohibiting computer use or ability to comply with study procedures * Residing in an institution or other living situation where health care decisions are not made by the participant (e.g., hospitalized, prisoners, living in a rehabilitation facility) * Does not complete baseline patient reported outcome (PRO) assessment items required to determine stratification or whether the survivor meets inclusion and exclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anatomic stage I breast cancer ajcc V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer cancer colorectal cancer colorectal neoplasm cutaneous melanoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm leukemia lymphoma melanoma sarcoma thyroid cancer thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anatomic stage I breast cancer ajcc V8 Anatomic stage II breast cancer ajcc V8 Anatomic stage III breast cancer ajcc V8 Clinical stage I cutaneous melanoma ajcc V8 Clinical stage II cutaneous melanoma ajcc V8 Clinical stage III cutaneous melanoma ajcc V8 Hematopoietic and lymphoid cell neoplasm Invasive malignant neoplasm Leukemia Lymphoma Malignant solid neoplasm Sarcoma Stage I colorectal cancer ajcc V8 Stage II colorectal cancer ajcc V8 Stage III colorectal cancer ajcc V8 Thyroid gland carcinoma

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.